Non-Dihydropyridine Calcium Channel Blockers Cause Constipation
Non-dihydropyridine calcium channel blockers (non-DHP CCBs), particularly verapamil, are well-established causes of constipation, whereas dihydropyridine CCBs are not typically associated with this side effect.
Mechanism and Clinical Evidence
Non-DHP CCBs (verapamil and diltiazem) cause constipation through direct inhibition of colonic motor activity. Verapamil is the most problematic agent, with constipation being one of its most common adverse effects, particularly in elderly patients 1, 2.
Key Differences Between CCB Classes:
Non-Dihydropyridines (Verapamil, Diltiazem):
- Verapamil specifically decreases intestinal motility leading to constipation, especially in elderly individuals 1
- Research demonstrates that verapamil significantly delays colonic transit at 48 hours (geometric center 5.2 vs 6.2 with placebo, p<0.01) 3
- Verapamil strongly inhibits sigmoid myoelectric response to meals, reducing normal colonic motor function 4
- The constipating effect is dose-dependent and occurs through reduced colonic transit, not upper GI effects 3
Dihydropyridines (Amlodipine, Nifedipine, Felodipine):
- Primary side effects are peripheral edema, headache, flushing, and reflex tachycardia 1, 5
- Constipation is NOT a characteristic side effect of this class
- While nifedipine can inhibit colonic motor activity in research settings 4, constipation is not clinically significant with this class in practice
Clinical Management Considerations
When Prescribing Non-DHP CCBs:
For verapamil specifically:
- Consider it a potentially harmful medication in patients ≥75 years with chronic constipation 2
- If constipation develops, treat the constipation rather than necessarily discontinuing the drug 2
- The 2020 AHA/ACC guidelines note verapamil can be potentially harmful in certain populations, including those with severe symptoms 6
Caution is advised when combining non-DHP CCBs with beta-blockers due to increased risk of bradyarrhythmias 7, 8, 9, though this relates to cardiac effects rather than constipation.
Common Pitfall:
Do not confuse the side effect profiles of the two CCB classes. If a patient requires a CCB but has constipation concerns, choose a dihydropyridine (like amlodipine) rather than a non-dihydropyridine. Conversely, if constipation develops in a patient on verapamil or diltiazem, consider switching to a dihydropyridine CCB if the clinical indication allows 5.
The most commonly reported adverse effect of non-DHP CCBs for constipation is with verapamil 10, 11, making it the agent requiring the most vigilance for this side effect.